Hemostemix Inc. (TSXV:HEM)
Canada
· Delayed Price · Currency is CAD | Market Cap | 20.34M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -3.43M |
| Shares Out | 145.31M |
| EPS (ttm) | -0.04 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 149,797 |
| Average Volume | 121,780 |
| Open | 0.1350 |
| Previous Close | 0.1400 |
| Day's Range | 0.1300 - 0.1350 |
| 52-Week Range | 0.0350 - 0.4250 |
| Beta | -0.43 |
| RSI | 54.34 |
| Earnings Date | Jun 4, 2025 |
About Hemostemix
Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, which is in Phase II clinical trial for the treatment of vascular diseases, such as peripheral arterial disease, angina pectoris, and ischemia, as well as heart failure, ischemic and dilated cardiomyopathy, chronic limb threatening ischemia, vascular dementia, and brain function. The company also develops NCP-01, which is preclinical trial to evaluate ... [Read more]
Financial Performance
Financial StatementsNews
Hemostemix Closes Private Placement of $469,366
Calgary, Alberta--(Newsfile Corp. - June 17, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") announces the closing of a non brokered private placement wi...
Hemostemix Presents at TERMIS 2025, Freiburg, Germany
Freiburg, Germany--(Newsfile Corp. - May 20, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF), a leading Phase III clinical-stage biotechnology company developing autologous stem cell therapies for ...
Hemostemix Closes Private Placement of USD $336,500 at $0.295 per Share
Calgary, Alberta--(Newsfile Corp. - May 12, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"), per the Company's February 4, 2025 news release, closed the ...
Hemostemix at Invest Stuttgart
Calgary, Alberta--(Newsfile Corp. - May 8, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is poised to make a significant impact at Invest Stuttgart 20...
Hemostemix Engages PatentVest to Strengthen its Global Patent Portfolio
Calgary, Alberta--(Newsfile Corp. - April 23, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) a leader in the development of autologous stem cell therapy for the treatment of cardiovasc...
Hemostemix's Pitch to Wall Street: ACP-01 Vascular Dementia Trial will Generate $5,365,000, Capture Data, as a Phase 1 Clinical Trial
Calgary, Alberta--(Newsfile Corp. - March 17, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or "HEM"), an autologous angiogenic stem cell company that has safely treated...
Hemostemix and FireFly Neuroscience's Brain Network Analytics (BNA(TM)) Engage to Complete Phase 1 Vascular Dementia Clinical Trial of ACP-01
A growing body of clinical evidence supports the use of Firefly's FDA-Cleared BNA(TM) platform to study ACP-01 as a treatment for vascular dementia Calgary, Alberta--(Newsfile Corp. - March 6, 2025) -...
Hemostemix Sells Its 23rd ACP-01 Therapy Convertible Debenture
Calgary, Alberta--(Newsfile Corp. - March 5, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or "HEM"), an autologous angiogenic stem cell therapy company that has safely ...
RETRANSMISSION: Hemostemix Licenses CytoImmune's BioReactor Technologies
Calgary, Alberta--(Newsfile Corp. - February 20, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is delighted to announce a strategic breakthrough that s...
Hemostemix Licenses CytoImmune's BioReactor Technologies
Calgary, Alberta--(Newsfile Corp. - February 19, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is delighted to announce a strategic breakthrough that s...
Hemostemix Provides Corporate Update
Calgary, Alberta--(Newsfile Corp. - February 13, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") announces that, at the request of the Canadian Investmen...
Hemostemix PR Inc. Congratulates Luis Munoz Marin International Airport on Achieving CEIV Pharma Certification
San Juan, Puerto Rico--(Newsfile Corp. - February 11, 2025) - Hemostemix PR Inc. proudly congratulates Luis Muñoz Marín International Airport (SJU) on achieving the prestigious CEIV Pharma Certificati...
Hemostemix Contracts ProConsul to Ramp up Engagement with New Investors
Calgary, Alberta--(Newsfile Corp. - February 10, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is excited to announce that it has engaged ProConsul Cap...
CytoImmune Subscribes for 1,634,466 Hemostemix Common Shares
Calgary, Alberta--(Newsfile Corp. - February 4, 2025) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is delighted to announce that CytoImmune is subscribing USD...
Hemostemix Expands to the Dominican Republic
Calgary, Alberta--(Newsfile Corp. - February 3, 2025) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce its continued expansion, as the Comp...
Hemostemix Announces First Sales Orders for ACP-01
Calgary, Alberta--(Newsfile Corp. - January 29, 2025) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is very pleased to announce that its sales of ACP-01 Treatm...
Hemostemix Up-lists to TradeGateExchange in Germany
Calgary, Alberta--(Newsfile Corp. - January 27, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is very pleased to announce that its shares commenced tra...
Hemostemix Up-Lists to OTCQB While it Presents its Global Scale-Up Strategy at Two Investor Conferences in Puerto Rico
Calgary, Alberta--(Newsfile Corp. - January 23, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is very pleased to announce that its shares will commence...
Hemostemix Announces Grant of Stock Options
Calgary, Alberta--(Newsfile Corp. - January 22, 2025) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce that in accordance with its stock op...
Hemostemix Presents at Puerto Rico Investor Summits: Showcasing Global Scale-Up Strategy and Economic Impact
Calgary, Alberta--(Newsfile Corp. - January 20, 2025) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is proud to announce its participation in two highly antici...
Hemostemix Settlement via Depository Trust Company Plus OTCQB Update
Calgary, Alberta--(Newsfile Corp. - January 13, 2025) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce that the settlement of Hemostemix co...
Hemostemix and CytoImmune Amend Manufacturing Agreement to Accelerate Global Scale-Up
Calgary, Alberta--(Newsfile Corp. - January 9, 2025) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VF0) is pleased to announce amendments to its Manufacturing Services Agreement with CytoImmune Th...
Hemostemix announces incorporation of Hemostemix PR
Hemostemix Announces the Incorporation of Hemostemix PR Inc: 50% Reimbursement of R&D Expenses in Cash
Calgary, Alberta--(Newsfile Corp. - January 6, 2025) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it has incorporated Hemostemix PR Inc...
Hemostemix is Up-Listing in the USA to Generate Liquidity
Calgary, Alberta--(Newsfile Corp. - January 2, 2025) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it has applied to up-list its share...